Trials / Recruiting
RecruitingNCT04985318
Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 350 (estimated)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a real-world setting, and identify predicting factors in iTTP-patients with regard to persistent autoimmune activity, therapy guidance and risk of complications. The rational is to develop new treatment algorithms that optimize overall patient outcome and reduce treatment cost.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cablivi® | Intervention with Cablivi® take place outside of the study |
Timeline
- Start date
- 2021-03-25
- Primary completion
- 2034-12-12
- Completion
- 2034-12-12
- First posted
- 2021-08-02
- Last updated
- 2024-12-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04985318. Inclusion in this directory is not an endorsement.